多菌种合生元补充剂对血液透析患者肠道来源尿毒症毒素及微生物代谢产物的影响
多菌种合生元补充剂对血液透析患者肠道来源尿毒症毒素和微生物组代谢物的影响
Patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis frequently exhibit significant gut microbiota dysbiosis and increased intestinal permeability. These alterations enable the translocation of endotoxins and gut-derived uremic toxins-such as indoxyl sulfate and p-cresyl sulfate-into the systemic circulation, exacerbating systemic inflammation, elevating cardiovascular risk, and accelerating disease progression.
Multispecies synbiotic supplementation has emerged as a promising intervention to restore gut microbial equilibrium, strengthen intestinal barrier function, and reduce the systemic load of harmful microbial metabolites. Through modulation of inflammatory pathways and reduction of circulating uremic toxins, synbiotic hold potential to improve clinical outcomes in this vulnerable population.
Although preclinical and some clinical evidence suggests benefits of probiotic therapy, comprehensive clinical trials specifically examining multispecies synbiotic effects on gut inflammatory markers, gut derived metabolite profiles, and uremic toxin levels in hemodialysis patients remain limited. This pilot study aims to address this gap by investigating the biological and clinical effects of a 12-week multispecies regimen in adult maintenance hemodialysis patients.
研究概览
详细说明
Study Design and Objectives This investigation is a single-arm, open-label pilot trial designed to assess the impact of a multispecies synbiotic supplementation on gut microbial metabolites, markers of inflammation, and gut-derived uremic toxins (GDUTs) over 12 weeks in adults with in a group of hemodialysis patients.
Sample Size Justification This pilot study targets 30 participants, which provides adequate power (80%, alpha 0.05) to detect a medium effect size (Cohen's d = 0.6) on the primary outcome, serum indoxyl sulfate levels. Calculations based on expected changes from 8.0 mg/L to 6.5 mg/L with SD of 2.5 mg/L indicate a required sample size of ~24; the sample size accounts for potential dropouts to ensure study robustness.
Study Procedures
- Baseline assessments:
- Collection of serum biochemical markers,
- Measurement of serum and urine uremic toxins,
- Quantification of microbial metabolites.
- Intervention:
Participants will receive Renobiome multispecies synbiotic containing 30 billion CFUs per capsule, including strains of Lactobacillus salivarius LS 159, Lactobacillus pentosus LPE 588, and Lactococcus lactis LL 358.
- Dose: One capsule twice daily (morning and evening), with or without food, taken with room-temperature water.
- Storage: Capsules to be kept below 25°C, in a dry, light-protected environment.
- Follow-up and Monitoring:
- At 4 weeks: Monitoring and documentation of gastrointestinal symptoms and adverse events.
- At 12 weeks: Repeat evaluations identical to baseline, including blood and urine tests.
Compliance and Safety
- Adherence will be tracked via regular follow-up contacts.
- An adherence rate of 80-100% is considered acceptable.
- All adverse drug reactions and any unexpected events will be recorded throughout the study duration.
Biological Sample Collection and Laboratory Methods
• Blood Sampling: Serum Blood samples are collected separately from each participant. Blood samples are collected after an 8 to 12-hour fasting period, using sodium fluoride tubes, and kept on ice until transfer to the research laboratory. Once there, the samples are centrifuged at 3,000×g for 15 minutes at 4°C. The serum Blood samples are collected separately from each participant. Blood samples are collected after an 8 to 12-hour fasting period, using sodium fluoride tubes, and kept on ice until transfer to the research laboratory. Once there, the samples are centrifuged at 3,000×g for 15 minutes at 4°C. The serum aliquots (200 μL) is then transferred to sterile tubes and stored at -80°C until batch analysis.
- Biomarker Measurement:
- Before analysis, samples will be thawed at room temperature for 20 minutes.
- Quantification of inflammatory cytokines such as Interleukin-1(IL-1), Interleukin-6(IL-6), Tumor Necrosis Factor-alpha(TNF-α) using validated ELISA kits (Ziker Biological Technology Co., Ltd., Shenzhen, China).
- Measurement of microbial metabolites such as short-chain fatty acids (SCFA, e.g., butyric acid), indolelactic acid (ILA), and indolepropionic acid (IPA) will be conducted.
We measure serum levels of acetate, propionate, butyrate, and valerate, along with branched-chain SCFAs such as isobutyrate and isovalerate. These metabolite profiles are analyzed using ultraperformance liquid chromatography-mass spectrometry (UPLC-MS). In brief, 100 μL of each serum sample is mixed in 1.5-mL microtubes with 20 mg of NaCl, 10 mg of citric acid, 20 μL of 1 M HCl, and 100 μL of butanol. The mixture is vortexed for 2 minutes and then centrifuged at 18,000×g for 15 minutes. The resulting supernatant is transferred to fresh microtubes for analysis.
- Uremic Toxin Analysis:
- Concentrations of indoxyl sulfate (IS), p-cresyl sulfate (PCS),Indole-3-acetic (IAA), and indolelactic acid (ILA) in serum and urine will be determined by high-performance liquid chromatography-mass spectrometry (HPLC-MS) according to established protocols:
Briefly, for binding competition, 200μl serum to which we added 20μl 0.50mM 1-naphthalenesulfonic acid (internal standard) was vortex-mixed with 250μl 0.24M sodium octanoate (binding competitor).After incubation at room temperature for 5min, we added 2ml cold acetone to precipitate proteins. Following vortex-mixing and centrifuging at 4 ◦C, 1860×g for 20 min, the supernatant was transferred to 12mm×100mm, GL 14 glass test tubes and 2ml dichloromethane was added. After vortex-mixing and centrifuging at 4 ◦C, 1860×g for 10min, 200μl of the upper layer was transferred to glass autosampler vials, followed by addition of 20μl 1M HCl and 15μl was injected onto the HPLC. The HPLC analysis was performed on an Agilent 1100 series LC (Santa Clara, CA),and Agilent ChemStations software were used for the chromatographic analysis. The separation was carried out on a ZORBAX SB-C18 Solv Saver Plus HPLC column (5 μm, 3.0 mm×150 mm).at a flow rate of 0.6 ml/min. Mobile phase A is 0.2% trifluoroacetic acid in Milli-Q water and mobile phase B is 0.2% trifluoroacetic acid in acetonitrile. The analytical method consists of an isocratic run with 92% mobile phase A for 23 min.. Each analytical run was followed by a 1.3 min washout gradient to 100% B. Column temperature was 25 ◦C, and autosampler tray temperature was 6 ◦C. We quantified the analytes by using the analyte to standard peak area ratio on a Agilent 1100 High Performance Fluorescence detector G1321A and Agilent 1100 Series UV-Visible detectors G1314A. Detector settings were λex 260 nm/λem288nm for p-cresyl sulfate and λex 280 nm/λem 390nm for indoxyl sulfate, indole-3-acetic acid(IAA), indolelactic acid (ILA) and internal standard.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Paik Seong Lim, PhD
- 电话号码:+886935045292
- 邮箱:jamespslim@gmail.com
研究联系人备份
- 姓名:Ming Ying Wu, MS/MSc
- 电话号码:+886933682221
- 邮箱:ying5430@gmail.com
学习地点
-
-
Wuqi District
-
Taichung、Wuqi District、台湾、435
- 招聘中
- Tungs' Taichung Metroharbour Hospital
-
接触:
- Paik Seong Lim, PhD
- 电话号码:+886935045292
- 邮箱:jamespslim@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months
Exclusion Criteria:
- Use of probiotic supplements within the last month;
- Hospitalization within the past month for acute infections or CKD-related complications;
- History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);
- Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;
- Use of antibiotics or immunosuppressive therapy within the preceding three months.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Multispecies synbiotic
Participants will receive Renobiome multispecies synbiotic containing 30 billion CFUs per capsule, including strains of Lactobacillus rhamnosus (strain ID pending), Lactobacillus salivarius LS 159, Lactobacillus pentosus LPE 588, and Lactococcus lactis LL 358.
|
Participants will receive Renobiome multispecies synbiotic containing 30 billion CFUs per capsule, including strains of Lactobacillus rhamnosus (strain ID pending), Lactobacillus salivarius LS 159, Lactobacillus pentosus LPE 588, and Lactococcus lactis LL 358.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate changes in levels of microbial metabolites
大体时间:1 years
|
Measurement of microbial metabolites (SCFA, e.g., butyric acid), indolelactic acid (ILA), and indolepropionic acid (IPA) concentrations. |
1 years
|
|
Measurement of serum uremic toxins
大体时间:1 years
|
• Concentrations of indoxyl sulfate (IS), p-cresyl sulfate (PCS), indoleacetic acid (IAA), and indolelactic acid (ILA) in serum and urine will be determined by high-performance liquid chromatography-mass spectrometry (HPLC-MS) |
1 years
|
|
Assess modulation of inflammatory markers
大体时间:1 years
|
• Quantification of inflammatory cytokines (IL-1, IL-6, TNF-α) Concentrations using validated ELISA kits. |
1 years
|
合作者和调查者
出版物和有用的链接
一般刊物
- Vaziri ND. Effect of Synbiotic Therapy on Gut-Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD. Clin J Am Soc Nephrol. 2016 Feb 5;11(2):199-201. doi: 10.2215/CJN.13631215. Epub 2016 Jan 15. No abstract available.
- Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014 Apr;25(4):657-70. doi: 10.1681/ASN.2013080905. Epub 2013 Nov 14.
- Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJ, de Almeida DC, Bassi EJ, Moraes-Vieira PM, Hiyane MI, Rodas AC, Peron JP, Aguiar CF, Reis MA, Ribeiro WR, Valduga CJ, Curi R, Vinolo MA, Ferreira CM, Camara NO. Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. J Am Soc Nephrol. 2015 Aug;26(8):1877-88. doi: 10.1681/ASN.2014030288. Epub 2015 Jan 14.
- Lim PS, Wang HF, Lee MC, Chiu LS, Wu MY, Chang WC, Wu TK. The Efficacy of Lactobacillus-Containing Probiotic Supplementation in Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. J Ren Nutr. 2021 Mar;31(2):189-198. doi: 10.1053/j.jrn.2020.07.002. Epub 2020 Sep 6.
- Meijers BK, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant. 2011 Mar;26(3):759-61. doi: 10.1093/ndt/gfq818. No abstract available.
- Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML. Uremic toxicity: present state of the art. Int J Artif Organs. 2001 Oct;24(10):695-725.
- Ramezani A, et al. Gut microbiome in CKD: challenges and opportunities. Transl Res. 2016.
- Gryp T, et al. Gut microbiota and uremic toxins in chronic kidney disease: friends or foes? Toxins. 2017.
- Barreto FC, et al. Indoxyl sulfate, p-cresyl sulfate and outcomes in CKD patients. J Am Soc Nephrol. 2009.
- Felizardo RJF, et al. The interplay between gut microbiota, inflammation, and CKD progression. Front Med. 2017.
- Vanholder R, et al. Uremic toxins and gut microbiota in CKD: therapeutic implications. Clin J Am Soc Nephrol. 2014.
- Evenepoel P, et al. Impact of dietary fiber and prebiotics on CKD progression. Kidney Int. 2021.
- Wong J, et al. Intestinal microbiome in patients with CKD: alterations and therapeutic potential. Nat Rev Nephrol. 2014.
- Anders HJ, et al. Dysbiosis and kidney diseases: lessons learned from translational research. Kidney Int. 2018.
- Vaziri ND, et al. Chronic kidney disease, dysbiosis, and the intestinal microbiome. J Ren Nutr. 2012.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.